Advanced
  Home Compare Reports

Comparison with Similar Reports

Proteomics Market by Component (Instruments, Reagents, and Services) and Application (Drug Discovery, Disease Diagnosis, and Others): Opportunity Anal...

Publisher:        Allied Market Research

# of Pages:        225

Rating: 

1 User License $5,370

Publication Date:  March, 2019

Price:       $5,370 / User License




Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top winning strategies
3.2.2. Top investment pockets
3.2.3. Top player positioning

3.3. Porter’s five forces analysis
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in popularity of personalized medicines
3.4.1.2. Upsurge in R&D expenditure
3.4.1.3. Technological advancements associated with proteomics components

3.4.2. Restraints

3.4.2.1. High costs associated with proteomics components
3.4.2.2. Dearth of skilled professionals

3.4.3. Opportunities

3.4.3.1. Lucrative opportunities associated with biomarker identification
3.4.3.2. Developments in mass spectrometry-based proteomics

Chapter: 4: PROTEOMICS MARKET, BY COMPONENT

4.1. Overview

4.1.1. Market size and forecast

4.2. Reagents

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Microarray

4.2.3.1. Market size and forecast

4.2.4. Spectrometry

4.2.4.1. Market size and forecast

4.2.5. X-ray crystallography

4.2.5.1. Market size and forecast

4.2.6. Chromatography

4.2.6.1. Market size and forecast

4.2.7. Electrophoresis

4.2.7.1. Market size and forecast

4.2.8. Immunoassay

4.2.8.1. Market size and forecast

4.2.9. Protein fractionation reagents

4.2.9.1. Market size and forecast

4.2.10. Market analysis, by country

4.3. Instruments

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Microarray

4.3.3.1. Market size and forecast

4.3.4. Spectrometry

4.3.4.1. Market size and forecast

4.3.4.1.1. Mass spectrometry

4.3.4.1.1.1. Market size and forecast

4.3.4.1.2. NMR spectrometry

4.3.4.1.2.1. Market size and forecast

4.3.5. Chromatography

4.3.5.1. Market size and forecast

4.3.5.1.1. HPLC systems

4.3.5.1.1.1. Market size and forecast

4.3.5.1.2. Ion chromatography

4.3.5.1.2.1. Market size and forecast

4.3.5.1.3. Affinity chromatography

4.3.5.1.3.1. Market size and forecast

4.3.5.1.4. Supercritical fluid chromatography

4.3.5.1.4.1. Market size and forecast

4.3.6. Electrophoresis

4.3.6.1. Market size and forecast

4.3.7. Surface plasmon resonance

4.3.7.1. Market size and forecast

4.3.8. X-ray crystallography

4.3.8.1. Market size and forecast

4.3.9. Protein fractionation systems

4.3.9.1. Market size and forecast

4.3.10. Market analysis, by country

4.4. Services

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country

Chapter: 5: PROTEOMICS MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Drug discovery

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Disease diagnosis

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

5.4. Others

5.4.1. Market size and forecast
5.4.2. Market analysis, by country

Chapter: 6: PROTEOMICS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. proteomics market, by component
6.2.2.1.2. U.S. proteomics market, by application

6.2.2.2. Canada

6.2.2.2.1. Canada proteomics market, by component
6.2.2.2.2. Canada proteomics market, by application

6.2.2.3. Mexico

6.2.2.3.1. Mexico proteomics market, by component
6.2.2.3.2. Mexico proteomics market, by application

6.2.3. North America proteomics market, by component
6.2.4. North America proteomics market, by application

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Germany proteomics market, by component
6.3.2.1.2. Germany proteomics market, by application

6.3.2.2. France

6.3.2.2.1. France proteomics market, by component
6.3.2.2.2. France proteomics market, by application

6.3.2.3. UK

6.3.2.3.1. UK proteomics market, by component
6.3.2.3.2. UK proteomics market, by application

6.3.2.4. Italy

6.3.2.4.1. Italy proteomics market, by component
6.3.2.4.2. ITALY proteomics market, by application

6.3.2.5. Spain

6.3.2.5.1. Spain proteomics market, by component
6.3.2.5.2. Spain proteomics market, by application

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe proteomics market, by component
6.3.2.6.2. Rest of Europe proteomics market, by application

6.3.3. Europe proteomics market, by component
6.3.4. Europe proteomics market, by application

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities

6.4.1.1. Japan

6.4.1.1.1. Japan proteomics market, by component
6.4.1.1.2. Japan proteomics market, by application

6.4.1.2. China

6.4.1.2.1. China proteomics market, by component
6.4.1.2.2. China proteomics market, by application

6.4.1.3. India

6.4.1.3.1. India proteomics market, by component
6.4.1.3.2. India proteomics market, by application

6.4.1.4. Australia

6.4.1.4.1. Australia proteomics market, by component
6.4.1.4.2. Australia proteomics market, by application

6.4.1.5. South Korea

6.4.1.5.1. South Korea proteomics market, by component
6.4.1.5.2. South Korea proteomics market, by application

6.4.1.6. Rest of Asia-Pacific

6.4.1.6.1. Rest of Asia-Pacific proteomics market, by component
6.4.1.6.2. Rest of Asia-Pacific proteomics market, by application

6.4.2. Asia-Pacific proteomics market, by component
6.4.3. Asia-Pacific proteomics market, by application

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil proteomics market, by component
6.5.2.1.2. Brazil proteomics market, by application

6.5.2.2. Saudi Arabia

6.5.2.2.1. Saudi Arabia proteomics market, by component
6.5.2.2.2. Saudi Arabia proteomics market, by application

6.5.2.3. South Africa

6.5.2.3.1. South Africa proteomics market, by component
6.5.2.3.2. South Africa proteomics market, by application

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA proteomics market, by component
6.5.2.4.2. Rest of LAMEA proteomics market, by application

6.5.3. LAMEA proteomics market, by component
6.5.4. LAMEA proteomics market, by application

Chapter: 7: COMPANY PROFILES

7.1. AGILENT TECHNOLOGIES, INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. DANAHER CORPORATION (BECKMAN COULTER, INC.)

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. LI-COR, INC.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio

7.4. PERKINELMER INC.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product Portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. THERMO FISHER SCIENTIFIC, INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. HORIBA, LTD.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance

7.7. BIO-RAD LABORATORIES, INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product type Portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. BRUKER CORPORATION (BECKMAN COULTER, INC.)

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product type portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. GE HEALTHCARE (GENERAL ELECTRIC)

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance

7.10. WATERS CORPORATION (BECKMAN COULTER, INC.)

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product type portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments

Remote Patient Monitoring (RPM) Market by Product (Software, Services, Devices, Cardiology, Neurological, BP Monitors, Neonatal, Weight, Temperature, ...

Publisher:        MarketsandMarkets

# of Pages:        200

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS AND EXCLUSIONS 28
1.3 MARKET SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 YEARS CONSIDERED FOR THE STUDY 30
1.4 CURRENCY 30
1.5 LIMITATIONS 30
1.6 STAKEHOLDERS 31
1.7 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
2.2 RESEARCH METHODOLOGY STEPS 32
FIGURE 1 RESEARCH METHODOLOGY: REMOTE PATIENT MONITORING MARKET 32
FIGURE 2 RESEARCH DESIGN 33
2.2.1 SECONDARY DATA 33
2.2.1.1 Key data from secondary sources 34
2.2.2 PRIMARY DATA 34
FIGURE 3 PRIMARY SOURCES 35
2.2.2.1 Key data from primary sources 36
2.2.2.2 Breakdown of primary sources 36
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 36
2.3 MARKET SIZE ESTIMATION 37
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 37
FIGURE 6 ESTIMATION OF THE MARKET SIZE FOR REMOTE PATIENT MONITORING SOFTWARE & SERVICES THROUGH THE ADOPTION-BASED APPROACH 38
FIGURE 7 ESTIMATION OF THE GLOBAL REMOTE PATIENT MONITORING MARKET SIZE THROUGH THE ADOPTION-BASED APPROACH 38
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 41
FIGURE 8 DATA TRIANGULATION METHODOLOGY 41
2.5 ASSUMPTIONS FOR THE STUDY 42
2.6 COVID-19-SPECIFIC ASSUMPTIONS 42
2.7 RISK ASSESSMENT 43
TABLE 1 LIMITATIONS AND ASSOCIATED RISKS 43
 
3 EXECUTIVE SUMMARY 44
FIGURE 9 REMOTE PATIENT MONITORING MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 44
FIGURE 10 REMOTE PATIENT MONITORING MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 45
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE REMOTE PATIENT MONITORING MARKET 46
4 PREMIUM INSIGHTS 47
4.1 REMOTE PATIENT MONITORING: MARKET OVERVIEW 47
FIGURE 12 COST BENEFITS OF TELEHEALTH & TELEMEDICINE COUPLED WITH THE RISING TECHNOLOGICAL ADVANCEMENTS IN REMOTE PATIENT MONITORING DEVICES ARE THE KEY GROWTH DRIVERS FOR THIS MARKET 47
4.2 REMOTE PATIENT MONITORING MARKET, BY END USER 48
FIGURE 13 PROVIDERS ACCOUNTED FOR THE LARGEST SHARE OF
THE RPM MARKET IN 2021 48
4.3 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET,
BY PRODUCT & COUNTRY (2021) 48
FIGURE 14 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN NORTH AMERICA FOR REMOTE PATIENT MONITORING IN 2021 48
4.4 GEOGRAPHICAL SNAPSHOT OF THE REMOTE PATIENT MONITORING MARKET 49
FIGURE 15 ASIA PACIFIC MARKET TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
FIGURE 16 REMOTE PATIENT MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.2.1 DRIVERS 51
5.2.1.1 Rising geriatric population and the growing need to expand healthcare access 51
TABLE 2 GLOBAL OVERVIEW OF THE RISE IN AGING POPULATION (MILLION) 51
5.2.1.2 Cost benefits of telehealth and remote patient monitoring 52
TABLE 3 CHRONIC DISEASES AND COST BURDEN IN THE US:
POTENTIAL FOR SAVINGS (2020) 52
5.2.1.3 Benefits of RPM to reduce the burden on medical resources 52
5.2.1.4 Advancements in telecommunications 53
5.2.1.5 Increasing investments in telehealth & RPM 53
5.2.2 RESTRAINTS 54
5.2.2.1 Regulatory variations across regions 54
TABLE 4 US: STATE-WISE REGULATORY REQUIREMENTS FOR TELEHEALTH 54
5.2.2.2 Healthcare fraud 55
5.2.2.3 Informal usage of social media practices 55
 
5.2.3 OPPORTUNITIES 56
5.2.3.1 Role and impact of AI in remote patient monitoring 56
5.2.3.2 High utility of RPM in combating infectious diseases & epidemics 57
5.2.3.3 Significant opportunities in data monetization of patient data 57
5.2.4 CHALLENGES 58
5.2.4.1 Data privacy concerns, healthcare affordability,
and limited awareness 58
5.2.4.2 Data accessibility issues 58
5.3 IMPACT OF COVID-19 ON THE REMOTE PATIENT MONITORING MARKET 59
5.4 PRICING AND REIMBURSEMENT ANALYSIS 61
TABLE 5 CPT CDES AND REIMBURSEMENT ANALYSIS OF US RPM MARKET 61
5.5 VALUE CHAIN ANALYSIS 61
FIGURE 17 REMOTE PATIENT MONITORING MARKET: VALUE CHAIN 62
5.6 ECOSYSTEM ANALYSIS 63
FIGURE 18 REMOTE PATIENT MONITORING MARKET: ECOSYSTEM ANALYSIS 63
5.7 TECHNOLOGY ANALYSIS 64
TABLE 6 DIGITAL TECHNOLOGY ENABLERS: BENEFITS AND EXAMPLES
IN THE REMOTE PATIENT MONITORING MARKET 64
5.8 END-USER ASSESSMENT OF RPM MARKET: US 65
5.8.1 DIGITAL TECHNOLOGY ENABLERS: BENEFITS AND EXAMPLES
IN THE REMOTE PATIENT MONITORING MARKET 65
TABLE 7 ADOPTION OF REMOTE PATIENT MONITORING AMONG END-USERS IN US (%) 66
5.9 REMOTE PATIENT MONITORING MARKET: PREVALENT SALES CHANNELS 67
FIGURE 19 COMMERCIALISATION STRATEGIES 67
5.10 KEY INDUSTRY TRENDS 68
5.11 OVERVIEW OF USE CASES 69
TABLE 8 REMOTE PATIENT MONITORING USE CASES 69
TABLE 9 BASIC AND ADVANCED CAPABILITIES OF RPM SERVICES 70
5.12 INTRODUCTION 70
TABLE 10 REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 71
5.13 SOFTWARE AND SERVICES 71
5.13.1 CONVENIENCE AND THE HIGH UTILITY OF RPM ARE THE KEY FACTORS DRIVING THE DEMAND FOR REMOTE MONITORING SOFTWARE & SERVICES 71
TABLE 11 REMOTE PATIENT MONITORING MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2020–2027 (USD MILLION) 72
TABLE 12 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR SOFTWARE AND SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 13 EUROPE: REMOTE PATIENT MONITORING MARKET FOR SOFTWARE AND SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 73
5.14 DEVICES 73
TABLE 14 REMOTE PATIENT MONITORING MARKET FOR DEVICES, BY TYPE,
2020–2027 (USD MILLION) 74
TABLE 15 REMOTE PATIENT MONITORING MARKET FOR DEVICES,
2020–2027 (USD MILLION) 74
TABLE 16 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR DEVICES,
BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 17 EUROPE: REMOTE PATIENT MONITORING MARKET FOR DEVICES,
BY COUNTRY, 2020–2027 (USD MILLION) 75
5.14.1 CARDIAC MONITORING DEVICES 75
5.14.1.1 The rising incidence of cardiovascular diseases drives the demand for ECG monitors, thus, driving the market growth in this segment 75
TABLE 18 REMOTE PATIENT MONITORING MARKET FOR CARDIAC MONITORING DEVICES, BY REGION, 2020–2027 (USD MILLION) 76
TABLE 19 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR CARDIAC MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 20 EUROPE: REMOTE PATIENT MONITORING MARKET FOR CARDIAC MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 21 REMOTE PATIENT MONITORING MARKET FOR CARDIAC MONITORING DEVICES, BY TYPE, 2020–2027 (USD MILLION) 77
5.14.2 BLOOD PRESSURE MONITORING DEVICES 78
5.14.2.1 Convenience and the growing demand for blood pressure meters have ensured high market growth in this segment 78
TABLE 22 REMOTE PATIENT MONITORING MARKET FOR BLOOD PRESSURE MONITORING DEVICES, BY REGION, 2020–2027 (USD MILLION) 78
5.14.3 NEUROLOGICAL MONITORING DEVICES 78
5.14.3.1 Growing prevalence of neurological diseases to drive the growth of this segment 78
TABLE 23 REMOTE PATIENT MONITORING MARKET FOR NEUROLOGICAL MONITORING DEVICES, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 24 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR NEUROLOGICAL MONITORING DEVICES, BY COUNTRY,
2020–2027 (USD MILLION) 79
TABLE 25 EUROPE: REMOTE PATIENT MONITORING MARKET FOR NEUROLOGICAL MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 80
5.14.4 RESPIRATORY MONITORING DEVICES 80
5.14.4.1 The growing adoption of pulse oximeters for self-monitoring during the COVID-19 pandemic is a key factor driving the market growth of this segment 80
TABLE 26 REMOTE PATIENT MONITORING MARKET FOR RESPIRATORY MONITORING DEVICES, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 27 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR RESPIRATORY MONITORING DEVICES, BY COUNTRY,
2020–2027 (USD MILLION) 81
TABLE 28 EUROPE: REMOTE PATIENT MONITORING MARKET FOR RESPIRATORY MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 82
5.14.5 MULTIPARAMETER MONITORING DEVICES 82
5.14.5.1 The increasing prevalence of chronic diseases is a major factor driving the market growth for this segment 82
TABLE 29 REMOTE PATIENT MONITORING MARKET FOR MULTIPARAMETER MONITORING DEVICES, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 30 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR MULTIPARAMETER MONITORING DEVICES, BY COUNTRY,
2020–2027 (USD MILLION) 83
TABLE 31 EUROPE: REMOTE PATIENT MONITORING MARKET FOR MULTIPARAMETER MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 83
5.14.6 BLOOD GLUCOSE MONITORING DEVICES 84
5.14.6.1 Growth in the global diabetic population will ensure a strong demand for blood glucose monitoring devices 84
TABLE 32 REMOTE PATIENT MONITORING MARKET FOR BLOOD GLUCOSE MONITORING DEVICES, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 33 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR BLOOD GLUCOSE MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 34 EUROPE: REMOTE PATIENT MONITORING MARKET FOR BLOOD GLUCOSE MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 85
5.14.7 FETAL & NEONATAL MONITORING DEVICES 86
5.14.7.1 Rising number of preterm births globally, to ensure the strong demand for RPM solutions in this segment 86
TABLE 35 REMOTE PATIENT MONITORING MARKET FOR FETAL & NEONATAL MONITORING DEVICES, BY REGION, 2020–2027 (USD MILLION) 86
TABLE 36 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR FETAL & NEONATAL MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 37 EUROPE: REMOTE PATIENT MONITORING MARKET FOR FETAL & NEONATAL MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 87
5.14.8 WEIGHT MONITORING DEVICES 87
5.14.8.1 Rising obesity levels ensure a strong demand for weight monitoring devices, thus driving the market growth for this segment 87
TABLE 38 REMOTE PATIENT MONITORING MARKET FOR WEIGHT MONITORING DEVICES, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 39 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR WEIGHT MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 40 EUROPE: REMOTE PATIENT MONITORING MARKET FOR WEIGHT MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 89
5.14.9 OTHER MONITORING DEVICES 89
TABLE 41 REMOTE PATIENT MONITORING MARKET FOR OTHER MONITORING DEVICES, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 42 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR OTHER MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 43 EUROPE: REMOTE PATIENT MONITORING MARKET FOR OTHER MONITORING DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 90
5.15 INTRODUCTION 91
TABLE 44 REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 91
5.16 PROVIDERS 91
TABLE 45 REMOTE PATIENT MONITORING MARKET FOR PROVIDERS, BY TYPE,
2020–2027 (USD MILLION) 92
TABLE 46 REMOTE PATIENT MONITORING MARKET FOR PROVIDERS, BY REGION, 2020–2027 (USD MILLION) 92
TABLE 47 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR PROVIDERS, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 48 EUROPE: REMOTE PATIENT MONITORING MARKET FOR PROVIDERS,
BY COUNTRY, 2020–2027 (USD MILLION) 93
5.16.1 HOSPITALS AND CLINICS 93
5.16.1.1 Hospitals and clinics contribute to the highest share of the providers market in the remote patient monitoring market in 2021 93
TABLE 49 REMOTE PATIENT MONITORING MARKET FOR HOSPITALS AND CLINICS,
BY REGION, 2020–2027 (USD MILLION) 94
TABLE 50 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 51 EUROPE: REMOTE PATIENT MONITORING MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2020–2027 (USD MILLION) 95
5.16.2 HOME CARE SETTINGS AND LONG-TERM CARE CENTERS 95
5.16.2.1 A rise in the global geriatric population requiring long-term care to support the growth of this end-user segment 95
TABLE 52 REMOTE PATIENT MONITORING MARKET FOR HOME CARE SETTINGS AND LONG-TERM CARE CENTERS, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 53 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR HOME CARE SETTINGS AND LONG-TERM CARE CENTERS, BY COUNTRY,
2020–2027 (USD MILLION) 96
TABLE 54 EUROPE: REMOTE PATIENT MONITORING MARKET FOR HOME CARE SETTINGS AND LONG-TERM CARE CENTERS, BY COUNTRY,
2020–2027 (USD MILLION) 97
5.16.3 AMBULATORY CARE CENTRES 97
5.16.3.1 The gradual shift of patient care from inpatient to outpatient settings drives the growth of this end-user segment 97
TABLE 55 REMOTE PATIENT MONITORING MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2020–2027 (USD MILLION) 98
TABLE 56 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR AMBULATORY CARE CENTERS, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 57 EUROPE: REMOTE PATIENT MONITORING MARKET FOR AMBULATORY CARE CENTERS, BY COUNTRY, 2020–2027 (USD MILLION) 98
5.16.4 OTHER PROVIDERS 99
TABLE 58 REMOTE PATIENT MONITORING MARKET FOR OTHER PROVIDERS,
BY REGION, 2020–2027 (USD MILLION) 99
TABLE 59 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR OTHER PROVIDERS, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 60 EUROPE: REMOTE PATIENT MONITORING MARKET FOR OTHER PROVIDERS, BY COUNTRY, 2020–2027 (USD MILLION) 100
5.17 PAYERS 100
5.17.1 INCREASING REIMBURSEMENTS FOR REMOTE PATIENT MONITORING TO DRIVE THE SEGMENT GROWTH 100
TABLE 61 REMOTE PATIENT MONITORING MARKET FOR PAYERS, BY REGION,
2020–2027 (USD MILLION) 101
TABLE 62 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR PAYERS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 63 EUROPE: REMOTE PATIENT MONITORING MARKET FOR PAYERS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
 
5.18 PATIENTS 102
5.18.1 COST-BENEFITS AND THE EMERGENCE OF ADVANCED WEARABLE MONITORS TO SUPPORT THE DEMAND FOR RPM DEVICES AMONG PATIENTS 102
TABLE 64 REMOTE PATIENT MONITORING MARKET FOR PATIENTS, BY REGION,
2020–2027 (USD MILLION) 102
TABLE 65 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET FOR PATIENTS,
BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 66 EUROPE: REMOTE PATIENT MONITORING MARKET FOR PATIENTS,
BY COUNTRY, 2020–2027 (USD MILLION) 103
5.18.2 OTHER END USERS 103
TABLE 67 REMOTE PATIENT MONITORING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 104
TABLE 68 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET
FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 69 EUROPE: REMOTE PATIENT MONITORING MARKET
FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 104
6 REMOTE PATIENT MONITORING MARKET, BY REGION 105
6.1 INTRODUCTION 106
TABLE 70 REMOTE PATIENT MONITORING MARKET, BY REGION,
2020–2027 (USD MILLION) 106
6.2 NORTH AMERICA 107
FIGURE 20 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET SNAPSHOT 107
TABLE 71 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 72 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 108
TABLE 73 NORTH AMERICA: REMOTE PATIENT MONITORING DEVICES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 74 NORTH AMERICA: REMOTE PATIENT MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION) 109
TABLE 75 NORTH AMERICA: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 109
6.2.1 US 109
6.2.1.1 The US accounted for the largest share of the
North American market in 2021 109
TABLE 76 US: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 110
TABLE 77 US: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 111
TABLE 78 US: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 111
TABLE 79 US: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 112
6.2.2 CANADA 112
6.2.2.1 The increasing rate of cardiac diseases promotes the adoption of RPM solutions, thus supplementing the market growth in Canada 112
TABLE 80 CANADA: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 113
TABLE 81 CANADA: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 113
TABLE 82 CANADA: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 114
TABLE 83 CANADA: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 114
6.3 EUROPE 115
FIGURE 21 EUROPE: REMOTE PATIENT MONITORING MARKET SNAPSHOT 115
TABLE 84 EUROPE: REMOTE PATIENT MONITORING MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 116
TABLE 85 EUROPE: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 86 EUROPE: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 117
TABLE 87 EUROPE: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 117
TABLE 88 EUROPE: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 118
6.3.1 GERMANY 118
6.3.1.1 Rapid digitization of healthcare systems and the rise in the geriatric population are key factors driving the market growth in Germany 118
TABLE 89 GERMANY: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 119
TABLE 90 GERMANY: REMOTE PATIENT MONITORING DEVICES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 91 GERMANY: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 120
TABLE 92 GERMANY: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 120
6.3.2 FRANCE 120
6.3.2.1 Favorable reimbursements and investments for telehealth is expected to support the market growth in France 120
TABLE 93 FRANCE: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 121
TABLE 94 FRANCE: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 121
TABLE 95 FRANCE: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 122
TABLE 96 FRANCE: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 122
6.3.3 UK 122
6.3.3.1 The increasing need to manage healthcare expenditure and a
severe shortage of physicians has boosted the adoption of
telehealth in the UK 122
TABLE 97 UK: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 98 UK: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 99 UK: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 124
TABLE 100 UK: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 124
6.3.4 ITALY 124
6.3.4.1 Established telehealth practices and a high density of elderly people in Italy is expected to drive the demand for RPM solutions 124
TABLE 101 ITALY: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 125
TABLE 102 ITALY: REMOTE PATIENT MONITORING DEVICES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 103 ITALY: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 126
TABLE 104 ITALY: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 126
6.3.5 SPAIN 126
6.3.5.1 A well-organized healthcare system indicates growing opportunities for the adoption of telehealth solutions in Spain 126
TABLE 105 SPAIN: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 106 SPAIN: REMOTE PATIENT MONITORING DEVICES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 107 SPAIN: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 128
TABLE 108 SPAIN: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 128
6.3.6 REST OF EUROPE (ROE) 128
TABLE 109 ROE: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 129
TABLE 110 ROE: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 129
TABLE 111 ROE: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 130
TABLE 112 ROE: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 130
6.4 ASIA PACIFIC 130
TABLE 113 ASIA PACIFIC: REMOTE PATIENT MONITORING MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 131
TABLE 114 ASIA PACIFIC: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 131
TABLE 115 ASIA PACIFIC: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 116 ASIA PACIFIC: REMOTE PATIENT MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION) 132
TABLE 117 ASIA PACIFIC: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 133
6.4.1 CHINA 133
6.4.1.1 China shows significant growth opportunities for advanced internet-based platforms in the RPM market 133
TABLE 118 CHINA: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 119 CHINA: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 120 CHINA: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 134
TABLE 121 CHINA: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 135
6.4.2 JAPAN 135
6.4.2.1 Universal healthcare coverage and an established insurance system makes Japan a prominent market for RPM services 135
TABLE 122 JAPAN: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 136
TABLE 123 JAPAN: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 136
TABLE 124 JAPAN: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 136
TABLE 125 JAPAN: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 137
6.4.3 INDIA 137
6.4.3.1 Favorable government policies and the high density of population in rural areas support the market growth for RPM solutions in India 137
TABLE 126 INDIA: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 127 INDIA: REMOTE PATIENT MONITORING DEVICES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 138
TABLE 128 INDIA: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 139
TABLE 129 INDIA: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 139
6.4.4 REST OF ASIA PACIFIC (ROAPAC) 139
TABLE 130 ROAPAC: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 140
TABLE 131 ROAPAC: REMOTE PATIENT MONITORING DEVICES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 132 ROAPAC: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 141
TABLE 133 ROAPAC: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 142
6.5 LATIN AMERICA 142
TABLE 134 LATIN AMERICA: REMOTE PATIENT MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 142
TABLE 135 LATIN AMERICA: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 143
TABLE 136 LATIN AMERICA: REMOTE PATIENT MONITORING DEVICES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 137 LATIN AMERICA: REMOTE PATIENT MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION) 143
TABLE 138 LATIN AMERICA: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 144
6.5.1 BRAZIL 144
6.5.1.1 Restricting informal consultations on social media to drive the market growth of RPM services in Brazil 144
TABLE 139 BRAZIL: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 140 BRAZIL: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 145
TABLE 141 BRAZIL: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 145
TABLE 142 BRAZIL: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 146
6.5.2 MEXICO 146
6.5.2.1 Increasing government initiatives to improve healthcare infrastructure in Mexico, thus driving the adoption of telehealth solutions 146
TABLE 143 MEXICO: REMOTE PATIENT MONITORING MARKET, BY TYPE,
2020–2027 (USD MILLION) 146
TABLE 144 MEXICO: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 147
TABLE 145 MEXICO: REMOTE PATIENT MONITORING MARKET, BY END USER,
2020–2027 (USD MILLION) 147
TABLE 146 MEXICO: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 148
6.5.3 REST OF LATIN AMERICA (ROLATAM) 148
TABLE 147 REST OF LATIN AMERICA: REMOTE PATIENT MONITORING MARKET, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 148 REST OF LATIN AMERICA: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 149 REST OF LATIN AMERICA: REMOTE PATIENT MONITORING MARKET,
BY END USER, 2020–2027 (USD MILLION) 149
TABLE 150 REST OF LATIN AMERICA: REMOTE PATIENT MONITORING FOR THE PROVIDERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 150
6.5.4 MIDDLE EAST & AFRICA 150
6.5.4.1 Healthcare infrastructural development and rising government initiatives for the adoption of RPM to drive the market growth
in this region 150
TABLE 151 MIDDLE EAST AND AFRICA: REMOTE PATIENT MONITORING MARKET,
BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 152 MIDDLE EAST AND AFRICA: REMOTE PATIENT MONITORING DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 153 MIDDLE EAST AND AFRICA: REMOTE PATIENT MONITORING MARKET,
BY END USER, 2020–2027 (USD MILLION) 151
TABLE 154 MIDDLE EAST AND AFRICA: REMOTE PATIENT MONITORING
FOR THE PROVIDERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
7 COMPETITIVE LANDSCAPE 153
7.1 OVERVIEW 153
FIGURE 22 THE KEY PLAYERS ADOPTED ORGANIC AND INORGANIC GROWTH STRATEGIES BETWEEN 2018 AND 2021 153
7.2 MARKET RANKING ANALYSIS, 2021 154
FIGURE 23 REMOTE PATIENT MONITORING MARKET, BY KEY PLAYER, 2021 154
7.3 COMPETITIVE SCENARIO 155
7.3.1 DEALS 155
7.3.2 PRODUCT LAUNCHES 156
7.3.3 OTHER DEVELOPMENTS 156
8 COMPANY EVALUATION MATRIX 157
8.1 INTRODUCTION 157
8.2 COMPANY EVALUATION MATRIX DEFINITIONS AND METHODOLOGY 157
TABLE 155 COMPANY EVALUATION MATRIX: CRITERIA 157
8.2.1 STARS 158
8.2.2 EMERGING LEADERS 158
8.2.3 PERVASIVE PLAYERS 158
8.2.4 EMERGING COMPANIES 158
FIGURE 24 MNM VENDOR DIVE COMPARISON MATRIX:
REMOTE PATIENT MONITORING MARKET 159
8.3 COMPANY EVALUATION QUADRANT FOR START-UPS 160
8.3.1 PROGRESSIVE COMPANIES 160
8.3.2 DYNAMIC COMPANIES 160
8.3.3 STARTING BLOCKS 160
8.3.4 RESPONSIVE COMPANIES 160
FIGURE 25 COMPANY EVALUATION QUADRANT FOR START-UPS:
REMOTE PATIENT MONITORING MARKET 161
8.4 COMPETITIVE BENCHMARKING 162
8.4.1 COMPANY PRODUCT FOOTPRINT 162
TABLE 156 COMPANY PRODUCT FOOTPRINT 162
8.4.2 COMPANY REGION FOOTPRINT 163
TABLE 157 COMPANY REGION FOOTPRINT 163
9 COMPANY PROFILES 164
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 KONINKLIJKE PHILIPS 164
FIGURE 26 KONINKLIJKE PHILIPS: COMPANY SNAPSHOT (2020) 164
9.2 MEDTRONIC 169
FIGURE 27 MEDTRONIC: COMPANY SNAPSHOT (2020) 169
9.3 OMRON HEALTHCARE INC. (A PART OF OMRON CORPORATION) 175
FIGURE 28 OMRON CORPORATION: COMPANY SNAPSHOT (2020) 175
9.4 GE HEALTHCARE 179
FIGURE 29 GE HEALTHCARE: COMPANY SNAPSHOT (2020) 179
9.5 CERNER CORPORATION 181
FIGURE 30 CERNER CORPORATION: COMPANY SNAPSHOT (2020) 181
9.6 SIEMENS HEALTHINEERS AG 184
FIGURE 31 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2019) 184
9.7 BOSTON SCIENTIFIC CORPORATION 186
FIGURE 32 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2020) 186
9.8 ABBOTT LABORATORIES 188
FIGURE 33 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 188
9.9 ALTEN CALSOFT LABS (A SUBSIDIARY OF ALTEN GROUP) 190
FIGURE 34 ALTEN GROUP: COMPANY SNAPSHOT (2020) 190
9.10 RESIDEO LIFE CARE SOLUTIONS 192
9.11 VIVIFY HEALTH, INC. 193
9.12 PREVENTICE SOLUTIONS 194
9.13 BIO-BEAT TECHNOLOGIES 196
9.14 VITALCONNECT 197
9.15 OTHER PLAYERS 198
9.15.1 WELCH ALLYN (A SUBSIDIARY OF HILL ROM SERVICES, INC.) 198
9.15.2 TELEDOC HEALTH INC. 198
9.15.3 DEXCOM, INC. 199
9.15.4 IRHYTHM TECHNOLOGIES 199
9.15.5 VIVALNK INC 200
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 201
10.1 DISCUSSION GUIDE 201
10.2 AVAILABLE CUSTOMIZATIONS 205
10.3 RELATED REPORTS 205
10.4 AUTHOR DETAILS 206

Digital Pathology Market by Product( ArtificiaI Intelligence, Scanner, Software, Storage), Type(Human, Veterinary), Application( Teleconsultation, Tra...

Publisher:        MarketsandMarkets

# of Pages:        242

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS AND EXCLUSIONS 32
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
FIGURE 1 DIGITAL PATHOLOGY INTEGRATION MARKET 32
1.3.2 YEARS CONSIDERED 33
1.4 CURRENCY 33
1.5 LIMITATIONS 33
1.6 STAKEHOLDERS 33
1.7 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 2 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 35
2.1.1.1 Key data from secondary sources 36
2.1.2 PRIMARY DATA 36
FIGURE 3 PRIMARY SOURCES 36
2.1.2.1 Key data from primary sources 37
2.1.2.2 Insights from primary experts 38
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 38
2.1.2.3 Breakdown of primary sources 39
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY CATEGORY, DESIGNATION, AND REGION 39
2.2 MARKET SIZE ESTIMATION 39
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 40
FIGURE 7 ILLUSTRATIVE EXAMPLE OF LEICA BIOSYSTEMS (SUBSIDIARY OF DANAHER CORPORATION) 40
FIGURE 8 SUPPLY-SIDE ANALYSIS: DIGITAL PATHOLOGY MARKET (2020) 41
FIGURE 9 BOTTOM-UP APPROACH 41
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
FIGURE 11 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE DIGITAL PATHOLOGY MARKET (2021–2026) 43
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 44
FIGURE 12 DATA TRIANGULATION METHODOLOGY 44
2.4 MARKET SHARE ESTIMATION 45
2.5 ASSUMPTIONS FOR THE STUDY 45
2.6 RISK ASSESSMENT 46
TABLE 1 RISK ASSESSMENT: DIGITAL PATHOLOGY MARKET 46
2.7 MARKET LIMITATIONS 46
2.7.1 METHODOLOGY-RELATED LIMITATIONS 46
2.7.2 SCOPE-RELATED LIMITATIONS 46
3 EXECUTIVE SUMMARY 47
FIGURE 13 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION) 47
FIGURE 14 DIGITAL PATHOLOGY MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 48
FIGURE 15 DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 48
FIGURE 16 DIGITAL PATHOLOGY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 49
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF THE DIGITAL PATHOLOGY MARKET 50
4 PREMIUM INSIGHTS 51
4.1 DIGITAL PATHOLOGY MARKET OVERVIEW 51
FIGURE 18 THE RISING PREVALENCE OF CANCER IS A KEY FACTOR EXPECTED TO DRIVE THE GROWTH OF THE DIGITAL PATHOLOGY MARKET 51
4.2 NORTH AMERICA: DIGITAL PATHOLOGY SOLUTIONS MARKET, BY END USER & COUNTRY (2020) 52
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN DIGITAL PATHOLOGY MARKET IN 2020 52
4.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
FIGURE 20 MARKET IN CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 53
4.4 REGIONAL MIX: DIGITAL PATHOLOGY MARKET (2021–2026) 54
FIGURE 21 NORTH AMERICA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026) 54
4.5 DIGITAL PATHOLOGY MARKET: DEVELOPING VS. DEVELOPED MARKETS 54
FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
FIGURE 23 DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 55
5.2.1 DRIVERS 56
5.2.1.1 Increasing adoption of digital pathology to enhance lab efficiency 56
5.2.1.2 Rising incidence of cancer 56
TABLE 2 GLOBAL CANCER INCIDENCE, 2018 VS. 2025 57
5.2.1.3 Growing applications of digital pathology in drug development and companion diagnostics 57
 
5.2.2 RESTRAINTS 58
5.2.2.1 High cost of digital pathology systems 58
5.2.3 OPPORTUNITIES 58
5.2.3.1 Introduction of affordable scanners for private pathology practices 58
5.2.3.2 Growing demand for personalized medicine 59
TABLE 3 US: GROWTH IN THE NUMBER OF PERSONALIZED MEDICINES (2008–2020) 59
5.2.3.3 High growth opportunities in emerging economies 60
5.2.4 CHALLENGES 60
5.2.4.1 Shortage of drained pathologists 60
TABLE 4 NUMBER OF INHABITANTS PER PATHOLOGIST, BY COUNTRY, 2020 60
5.3 COVID-19 IMPACT ANALYSIS 61
5.3.1 IMPACT OF COVID-19 ON THE DIGITAL PATHOLOGY MARKET 61
FIGURE 24 IMPACT OF COVID-19 ON THE DIGITAL PATHOLOGY MARKET 61
5.4 ECOSYSTEM MARKET MAP 62
FIGURE 25 DIGITAL PATHOLOGY MARKET: ECOSYSTEM MARKET MAP 62
5.5 TRENDS IN AVERAGE SELLING PRICE 63
FIGURE 26 DIGITAL PATHOLOGY MARKET: AVERAGE REGIONAL PRICES OF DIGITAL PATHOLOGY SCANNERS 63
5.6 IMPACT OF THE NEW IVD REGULATION ON DIFFERENT MARKETS 63
FIGURE 27 TIMELINE AND TRANSITION TO NEW MDR AND IVDR 64
5.6.1 IMPACT ON CLINICAL LAB SERVICES 65
5.6.2 IMPACT ON IVD 65
5.6.3 IMPACT ON DIGITAL PATHOLOGY 65
5.7 TECHNOLOGY ANALYSIS 66
5.7.1 ARTIFICIAL INTELLIGENCE (AI) IN DIGITAL PATHOLOGY 66
5.8 PATENT ANALYSIS 67
5.8.1 METHODOLOGY 67
5.8.2 PUBLICATION TRENDS 67
FIGURE 28 PUBLICATION TRENDS, 2015–2021 67
5.8.3 JURISDICTION ANALYSIS 67
FIGURE 29 JURISDICTION ANALYSIS, 2015–2021 68
5.8.4 TOP APPLICANTS 68
FIGURE 30 TOP APPLICANTS, 2015–2021 68
6 DIGITAL PATHOLOGY MARKET, BY PRODUCT 69
6.1 INTRODUCTION 70
TABLE 5 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 70
6.2 SCANNERS 70
6.2.1 SCANNERS ACCOUNTED FOR THE LARGEST SHARE OF THE DIGITAL PATHOLOGY PRODUCTS MARKET IN 2020 70
TABLE 6 SCANNING MAGNIFICATION AND APPLICATIONS 71
TABLE 7 DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS 71
TABLE 8 DIGITAL PATHOLOGY SCANNERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 73
TABLE 9 DIGITAL PATHOLOGY SCANNERS MARKET, BY REGION,
2019–2026 (USD MILLION) 73
TABLE 10 DIGITAL PATHOLOGY SCANNERS MARKET, BY REGION, 2019–2026 (UNITS) 74
TABLE 11 DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 74
6.2.1.1 Brightfield scanners 74
TABLE 12 BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS 74
TABLE 13 BRIGHTFIELD SCANNERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 75
6.2.1.2 Fluorescence scanners 76
TABLE 14 FLUORESCENCE SCANNERS OFFERED BY KEY MARKET PLAYERS 76
TABLE 15 FLUORESCENCE SCANNERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 76
6.2.1.3 Other scanners 77
TABLE 16 OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS 77
TABLE 17 OTHER SCANNERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 77
6.3 SOFTWARE 78
6.3.1 DIGITAL PATHOLOGY SOFTWARE OFFERS ANALYTICAL AND HIGHLY ADVANCED FUNCTIONS 78
TABLE 18 DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS 78
TABLE 19 DIGITAL PATHOLOGY SOFTWARE MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 79
TABLE 20 DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 79
6.3.1.1 Information management software 80
TABLE 21 INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS 80
TABLE 22 INFORMATION MANAGEMENT SOFTWARE MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 80
6.3.1.2 Image analysis software 81
TABLE 23 IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS 81
TABLE 24 IMAGE ANALYSIS SOFTWARE MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 81
6.3.1.3 Visualization software 82
TABLE 25 VISUALIZATION SOFTWARE OFFERED BY KEY MARKET PLAYERS 82
TABLE 26 VISUALIZATION SOFTWARE MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 82
6.4 COMMUNICATION SYSTEMS 83
6.4.1 INTRODUCTION OF CLOUD-BASED COMMUNICATION SYSTEMS TO PROPEL THE GROWTH OF THIS MARKET 83
TABLE 27 COMMUNICATION SYSTEMS USED IN DIGITAL PATHOLOGY 83
TABLE 28 COMMUNICATION SYSTEMS OFFERED BY KEY MARKET PLAYERS 84
TABLE 29 COMMUNICATION SYSTEMS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 84
 
6.5 STORAGE SYSTEMS 85
6.5.1 REQUIREMENT FOR THE SAFE AND RELIABLE STORAGE OF HIGH-QUALITY IMAGES TO ENSURE MARKET GROWTH 85
TABLE 30 STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS 85
TABLE 31 STORAGE SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 86
7 DIGITAL PATHOLOGY MARKET, BY TYPE 87
7.1 INTRODUCTION 88
TABLE 32 DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 88
7.2 HUMAN PATHOLOGY 88
7.2.1 THE COVID-19 PANDEMIC HAS LED TO AN INCREASING DEMAND FOR DIGITAL PATHOLOGY SOLUTIONS 88
TABLE 33 HUMAN DIGITAL PATHOLOGY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 89
7.3 VETERINARY PATHOLOGY 89
7.3.1 VETERINARY DIGITAL PATHOLOGY REDUCES THE TURNAROUND TIME FOR ANIMAL DISEASE DIAGNOSIS─KEY FACTOR DRIVING THE MARKET GROWTH 89
TABLE 34 VETERINARY DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 90
8 DIGITAL PATHOLOGY MARKET, BY APPLICATION 91
8.1 INTRODUCTION 92
TABLE 35 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 92
8.2 DRUG DISCOVERY 92
8.2.1 INCREASING R&D SPENDING TO DRIVE THE GROWTH OF THIS SEGMENT 92
TABLE 36 APPLICATIONS OF DIGITAL PATHOLOGY IN DRUG DISCOVERY 92
TABLE 37 DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY,
2019–2026 (USD MILLION) 93
8.3 DISEASE DIAGNOSIS 94
8.3.1 USE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIGITAL PATHOLOGY SOLUTIONS FOR DIAGNOSTIC PURPOSES TO DRIVE MARKET GROWTH 94
TABLE 38 DIGITAL PATHOLOGY MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY, 2019–2026 (USD MILLION) 95
8.4 TELECONSULTATION 95
8.4.1 GROWING NEED FOR ACCURATE & FAST DIAGNOSIS TO DRIVE THE ADOPTION OF TELECONSULTATION FOR NUMEROUS CLINICAL APPLICATIONS 95
TABLE 39 DIGITAL PATHOLOGY MARKET FOR TELECONSULTATION, BY COUNTRY,
2019–2026 (USD MILLION) 96
8.5 TRAINING & EDUCATION 97
8.5.1 DIGITAL PATHOLOGY CAN IMPROVE EDUCATION & TRAINING PROVIDED TO PATHOLOGISTS IN ACADEMIC INSTITUTES 97
TABLE 40 DIGITAL PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY, 2019–2026 (USD MILLION) 97
 
9 DIGITAL PATHOLOGY MARKET, BY END USER 98
9.1 INTRODUCTION 99
TABLE 41 DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION) 99
TABLE 42 DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER,
2019–2026 (USD MILLION) 99
TABLE 43 DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER,
2019–2026 (UNITS) 100
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 100
9.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST & FASTEST-GROWING END USERS OF THE DIGITAL PATHOLOGY MARKET 100
TABLE 44 DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 101
TABLE 45 DIGITAL PATHOLOGY SCANNERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION) 101
TABLE 46 DIGITAL PATHOLOGY SCANNERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (UNITS) 102
9.3 HOSPITALS AND REFERENCE LABORATORIES 102
9.3.1 INCREASING ADOPTION OF DIGITAL PATHOLOGY SOLUTIONS IN HOSPITALS TO DRIVE THE GROWTH OF THIS SEGMENT 102
TABLE 47 HOSPITAL DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS 103
TABLE 48 DIGITAL PATHOLOGY MARKET FOR HOSPITALS AND REFERENCE LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION) 104
TABLE 49 DIGITAL PATHOLOGY SCANNERS MARKET FOR HOSPITALS AND REFERENCE LABORATORIES COMPANIES, BY REGION, 2019–2026 (USD MILLION) 104
TABLE 50 DIGITAL PATHOLOGY SCANNERS MARKET FOR HOSPITALS AND REFERENCE LABORATORIES COMPANIES, BY REGION, 2019–2026 (UNITS) 105
9.4 ACADEMIC & RESEARCH INSTITUTES 105
9.4.1 FUNDING INVESTMENTS AND INITIATIVES TO BOOST THE GROWTH OF THIS END-USER SEGMENT IN THE DIGITAL PATHOLOGY MARKET 105
TABLE 51 DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY, 2019–2026 (USD MILLION) 106
TABLE 52 DIGITAL PATHOLOGY SCANNERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES COMPANIES, BY REGION, 2019–2026 (USD MILLION) 107
TABLE 53 DIGITAL PATHOLOGY SCANNERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES COMPANIES, BY REGION, 2019–2026 (UNITS) 107
10 DIGITAL PATHOLOGY MARKET, BY REGION 108
10.1 INTRODUCTION 109
TABLE 54 DIGITAL PATHOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION) 109
10.2 NORTH AMERICA 109
FIGURE 31 NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT 110
TABLE 55 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 110
TABLE 56 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 111
TABLE 57 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 111
TABLE 58 NORTH AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 111
TABLE 59 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE,
2019–2026 (USD MILLION) 112
TABLE 60 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 112
TABLE 61 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 112
TABLE 62 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION) 113
TABLE 63 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS) 113
10.2.1 US 113
10.2.1.1 Favorable reimbursement scenario for digital pathology in the
US to drive the adoption of digital pathology solutions 113
TABLE 64 US: CANCER INCIDENCE RATES, 2020 114
TABLE 65 US: DIGITAL PATHOLOGY CONFERENCES 115
TABLE 66 US: KEY MACROINDICATORS 115
TABLE 67 US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 115
TABLE 68 US: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 116
TABLE 69 US: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 116
TABLE 70 US: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 116
TABLE 71 US: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 117
TABLE 72 US: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 117
10.2.2 CANADA 117
10.2.2.1 Cancer awareness initiatives by the government to drive the market growth in Canada 117
TABLE 73 CANADA: CANCER INCIDENCE RATES, 2020 118
TABLE 74 CANADA: DIGITAL PATHOLOGY INITIATIVES AND FUNDING 119
TABLE 75 CANADA: KEY MACROINDICATORS 119
TABLE 76 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 120
TABLE 77 CANADA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 120
TABLE 78 CANADA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 120
TABLE 79 CANADA: DIGITAL PATHOLOGY MARKET, BY TYPE,
2019–2026 (USD MILLION) 121
TABLE 80 CANADA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 121
TABLE 81 CANADA: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 121
 
10.3 EUROPE 122
TABLE 82 EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 122
TABLE 83 EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 122
TABLE 84 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 123
TABLE 85 EUROPE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 123
TABLE 86 EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 123
TABLE 87 EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 124
TABLE 88 EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 124
TABLE 89 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER,
2019–2026 (USD MILLION) 124
TABLE 90 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER,
2019–2026 (UNITS) 125
10.3.1 UK 125
10.3.1.1 The UK is the largest market for digital pathology in Europe owing to rising government funding & initiatives 125
TABLE 91 CONFERENCES/COURSES HELD IN THE UK 126
TABLE 92 UK: KEY MACROINDICATORS 126
TABLE 93 UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 127
TABLE 94 UK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 127
TABLE 95 UK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 127
TABLE 96 UK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 128
TABLE 97 UK: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 128
TABLE 98 UK: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 128
10.3.2 GERMANY 129
10.3.2.1 High healthcare expenditure and supportive health insurance in Germany to drive the adoption of digital pathology solutions 129
TABLE 99 GERMANY: CANCER INCIDENCE RATES, 2020 129
TABLE 100 GERMANY: KEY MACROINDICATORS 130
TABLE 101 GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 130
TABLE 102 GERMANY: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 130
TABLE 103 GERMANY: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 131
TABLE 104 GERMANY: DIGITAL PATHOLOGY MARKET, BY TYPE,
2019–2026 (USD MILLION) 131
TABLE 105 GERMANY: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 131
TABLE 106 GERMANY: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 132
10.3.3 SWEDEN 132
10.3.3.1 Increasing government initiatives for the deployment of digital pathology solutions to drive the market growth in Sweden 132
TABLE 107 SWEDEN: CANCER INCIDENCE RATES, 2020 132
TABLE 108 SWEDEN: KEY MACROINDICATORS 133
TABLE 109 SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026(USD MILLION) 133
TABLE 110 SWEDEN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 134
TABLE 111 SWEDEN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 134
TABLE 112 SWEDEN: DIGITAL PATHOLOGY MARKET, BY TYPE,
2019–2026 (USD MILLION) 134
TABLE 113 SWEDEN: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 135
TABLE 114 SWEDEN: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 135
10.3.4 DENMARK 136
10.3.4.1 High prevalence of cancer to support the market growth in Denmark 136
FIGURE 32 DENMARK: CANCER PREVALENCE, 2012–2020 136
TABLE 115 DENMARK: CANCER INCIDENCE RATES, 2020 136
TABLE 116 DENMARK: KEY MACROINDICATORS 137
TABLE 117 DENMARK: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 137
TABLE 118 DENMARK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 138
TABLE 119 DENMARK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 138
TABLE 120 DENMARK: DIGITAL PATHOLOGY MARKET, BY TYPE,
2019–2026 (USD MILLION) 138
TABLE 121 DENMARK: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 139
TABLE 122 DENMARK: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 139
10.3.5 FRANCE 139
10.3.5.1 Increasing government funding and favorable insurance system among factors responsible for rising adoption of digital pathology solutions in France 139
TABLE 123 FRANCE: CANCER INCIDENCE RATES, 2020 140
TABLE 124 FRANCE: KEY MACROINDICATORS 140
TABLE 125 FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 141
TABLE 126 FRANCE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 141
TABLE 127 FRANCE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 141
TABLE 128 FRANCE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 142
TABLE 129 FRANCE: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 142
TABLE 130 FRANCE: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 142
10.3.6 REST OF EUROPE (ROE) 143
TABLE 131 ROE: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 143
TABLE 132 ROE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 143
TABLE 133 ROE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 144
TABLE 134 ROE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 144
TABLE 135 ROE: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 144
TABLE 136 ROE: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 145
10.4 ASIA PACIFIC (APAC) 145
TABLE 137 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 145
TABLE 138 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 146
TABLE 139 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 146
TABLE 140 ASIA PACIFIC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 146
TABLE 141 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE,
2019–2026 (USD MILLION) 147
TABLE 142 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 147
TABLE 143 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 147
TABLE 144 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION) 148
TABLE 145 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS) 148
10.4.1 CHINA 148
10.4.1.1 Favorable initiatives by the government for the adoption of telepathology in China 148
TABLE 146 CHINA: CANCER INCIDENCE RATES, 2020 149
TABLE 147 CHINA: KEY MACROINDICATORS 149
TABLE 148 CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 150
TABLE 149 CHINA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 150
TABLE 150 CHINA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 150
TABLE 151 CHINA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 151
TABLE 152 CHINA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 151
TABLE 153 CHINA: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 151
10.4.2 JAPAN 152
10.4.2.1 Universal healthcare reimbursement for driving the adoption of digital pathology solutions in Japan 152
TABLE 154 JAPAN: CANCER INCIDENCE RATES, 2020 152
TABLE 155 JAPAN: KEY MACROINDICATORS 152
TABLE 156 JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 153
TABLE 157 JAPAN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 153
TABLE 158 JAPAN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 153
TABLE 159 JAPAN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 154
TABLE 160 JAPAN: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 154
TABLE 161 JAPAN: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 154
10.4.3 INDIA 155
10.4.3.1 The growing number of cancer cases in India drive the market growth for digital pathology 155
TABLE 162 INDIA: CANCER INCIDENCE RATES, 2020 155
TABLE 163 INDIA: KEY MACROINDICATORS 156
TABLE 164 INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 156
TABLE 165 INDIA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 156
TABLE 166 INDIA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 157
TABLE 167 INDIA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 157
TABLE 168 INDIA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 157
TABLE 169 INDIA: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 158
10.4.4 REST OF ASIA PACIFIC (ROAPAC) 158
TABLE 170 ROAPAC: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 159
TABLE 171 ROAPAC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 159
TABLE 172 ROAPAC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 159
TABLE 173 ROAPAC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 174 ROAPAC: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 160
TABLE 175 ROAPAC: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 160
10.5 LATIN AMERICA 161
TABLE 176 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 161
TABLE 177 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 161
TABLE 178 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 162
TABLE 179 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 162
TABLE 180 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 162
TABLE 181 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 163
TABLE 182 LATIN AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 163
TABLE 183 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE,
2019–2026 (USD MILLION) 163
TABLE 184 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 164
TABLE 185 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 164
TABLE 186 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION) 165
TABLE 187 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS) 165
10.5.1 BRAZIL 165
10.5.1.1 Growing geriatric population and the subsequent increase in age-related disorders to drive the adoption of digital pathology solutions in Brazil 165
TABLE 188 BRAZIL: CANCER INCIDENCE RATES, 2020 166
TABLE 189 BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 166
TABLE 190 BRAZIL: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 166
TABLE 191 BRAZIL: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 167
TABLE 192 BRAZIL: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 167
TABLE 193 BRAZIL: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 167
TABLE 194 BRAZIL: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 168
10.5.2 MEXICO 168
10.5.2.1 The increasing burden of infectious diseases to drive the uptake of digital pathology in Mexico 168
TABLE 195 MEXICO: CANCER INCIDENCE RATES, 2020 168
TABLE 196 MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 169
TABLE 197 MEXICO: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 169
TABLE 198 MEXICO: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 169
TABLE 199 MEXICO: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION) 170
TABLE 200 MEXICO: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 170
TABLE 201 MEXICO: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 170
10.5.3 REST OF LATIN AMERICA (ROLATAM) 171
TABLE 202 ROLATAM: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 171
TABLE 203 ROLATAM: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 171
TABLE 204 ROLATAM: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 172
TABLE 205 ROLATAM: DIGITAL PATHOLOGY MARKET, BY TYPE,
2019–2026 (USD MILLION) 172
TABLE 206 ROLATAM: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 172
TABLE 207 ROLATAM: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 INFRASTRUCTURAL DEVELOPMENTS IN THE REGION TO BOOST THE ADOPTION OF TECHNOLOGICALLY ADVANCED PATHOLOGY SOLUTIONS 173
TABLE 208 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 174
TABLE 209 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 175
TABLE 210 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 175
TABLE 211 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION) 175
TABLE 212 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE,
2019–2026 (USD MILLION) 176
TABLE 213 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 176
TABLE 214 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER,
2019–2026 (USD MILLION) 176
TABLE 215 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET,
BY END USER, 2019–2026 (USD MILLION) 177
TABLE 216 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET,
BY END USER, 2019–2026 (UNITS) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT-TO-WIN 178
FIGURE 33 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE DIGITAL PATHOLOGY MARKET 179
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 180
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN THE DIGITAL PATHOLOGY MARKET 180
11.4 COMPETITIVE BENCHMARKING 181
TABLE 217 FOOTPRINT OF COMPANIES IN THE DIGITAL PATHOLOGY MARKET 181
TABLE 218 PRODUCT: COMPANY FOOTPRINT (25 COMPANIES) 182
TABLE 219 END USER: COMPANY FOOTPRINT (25 COMPANIES) 183
TABLE 220 REGION: COMPANY FOOTPRINT (26 COMPANIES) 184
11.5 COMPETITIVE LEADERSHIP MAPPING 185
11.5.1 STAR 185
11.5.2 EMERGING LEADERS 185
11.5.3 PERVASIVE PLAYERS 185
11.5.4 PARTICIPANTS 186
FIGURE 35 DIGITAL PATHOLOGY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020) 186
11.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES 187
11.6.1 PROGRESSIVE COMPANY 187
11.6.2 DYNAMIC COMPANY 187
11.6.3 STARTING BLOCK 187
11.6.4 RESPONSIVE COMPANY 187
FIGURE 36 DIGITAL PATHOLOGY MARKET: COMPETITIVE LEADERSHIP
MAPPING FOR OTHER COMPANIES (2020) 188
11.7 MARKET SHARE ANALYSIS 188
FIGURE 37 DIGITAL PATHOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020 189
11.8 COMPETITIVE SCENARIO 190
11.8.1 PRODUCT LAUNCHES AND APPROVALS 190
TABLE 221 PRODUCT LAUNCHES AND APPROVALS, 2019–2021 190
11.8.2 DEALS 191
TABLE 222 DEALS, 2019–2021 191
12 COMPANY PROFILES 193
(Business Overview, Products & services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 KEY PLAYERS 193
12.1.1 LEICA BIOSYSTEMS 193
TABLE 223 LEICA BIOSYSTEMS: BUSINESS OVERVIEW 193
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 194
12.1.2 KONINKLIJKE PHILIPS N.V. 198
TABLE 224 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW 198
FIGURE 39 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2020) 199
12.1.3 HAMAMATSU PHOTONICS 202
TABLE 225 HAMAMATSU PHOTONICS: BUSINESS OVERVIEW 202
FIGURE 40 HAMAMATSU PHOTONICS: COMPANY SNAPSHOT (2020) 203
12.1.4 F. HOFFMANN-LA ROCHE LTD. 205
TABLE 226 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 205
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 206
 
12.1.5 SECTRA AB 209
TABLE 227 SECTRA AB: BUSINESS OVERVIEW 209
FIGURE 42 SECTRA AB: COMPANY SNAPSHOT (2020) 210
12.1.6 AKOYA BIOSCIENCES 213
TABLE 228 AKOYA BIOSCIENCES: BUSINESS OVERVIEW 213
FIGURE 43 AKOYA BIOSCIENCES: COMPANY SNAPSHOT (2020) 213
12.1.7 3DHISTECH 215
TABLE 229 3DHISTECH: BUSINESS OVERVIEW 215
12.1.8 APOLLO ENTERPRISE IMAGING CORP. 217
TABLE 230 APOLLO ENTERPRISE IMAGING CORP.: BUSINESS OVERVIEW 217
12.1.9 XIFIN, INC. 219
TABLE 231 XIFIN, INC.: BUSINESS OVERVIEW 219
12.1.10 HURON DIGITAL PATHOLOGY 220
TABLE 232 HURON DIGITAL PATHOLOGY: BUSINESS OVERVIEW 220
12.1.11 VISIOPHARM 222
TABLE 233 VISIOPHARM: BUSINESS OVERVIEW 222
12.1.12 CORISTA 224
TABLE 234 CORISTA: BUSINESS OVERVIEW 224
12.1.13 INDICA LABS 226
TABLE 235 INDICA LABS: BUSINESS OVERVIEW 226
12.1.14 OBJECTIVE PATHOLOGY SERVICES 228
TABLE 236 OBJECTIVE PATHOLOGY SERVICES: BUSINESS OVERVIEW 228
12.1.15 OPTRASCAN, INC. 229
TABLE 237 OPTRASCAN, INC.: BUSINESS OVERVIEW 229
12.1.16 GLENCOE SOFTWARE, INC. 231
TABLE 238 GLENCOE SOFTWARE, INC.: BUSINESS OVERVIEW 231
12.1.17 AIFORIA TECHNOLOGIES OY 232
TABLE 239 AIFORIA TECHNOLOGIES OY: BUSINESS OVERVIEW 232
TABLE 240 PAIGE: BUSINESS OVERVIEW 234
12.1.19 INSPIRATA, INC. 236
TABLE 241 INSPIRATA, INC.: BUSINESS OVERVIEW 236
12.1.20 PROSCIA, INC. 238
TABLE 242 PROSCIA, INC.: BUSINESS OVERVIEW 238
12.2 OTHER PLAYERS 241
12.2.1 PATHAI 241
12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD. 241
12.2.3 MIKROSCAN TECHNOLOGIES, INC. 242
12.2.4 MOTIC DIGITAL PATHOLOGY 242
12.2.5 KANTERON SYSTEMS 242
*Details on Business Overview, Products & services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX 243
13.1 DISCUSSION GUIDE 243
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 247
13.3 AVAILABLE CUSTOMIZATIONS 249
13.4 RELATED REPORTS 249
13.5 AUTHOR DETAILS 250